Answer for NURS 8310 Week 11 Discussion 2 Factors That Impact Population Health Summary of the Selected Public Health Initiative
Sample
My selected public health initiative is the national action plan (NAP) for combating multidrug-resistant tuberculosis (MDR-TB). The United States (U.S.) initiated the NAP against the MDR-TB to expand global efforts to fight the disease, save lives, and prevent its spread both in the U.S. and worldwide. The NAP to combat the MDR-TB identifies a set of targeted interventions that address the core domestic and global challenges posed by MDR-TB (The United States Agency for International Development [USAID], 2020). The main goals of the NAP include strengthening domestic capacity to combat MDR-TB, improving the international capacity and collaboration against MDR-TB, and accelerating basic and applied research and development to combat MDR-TB (De Vries et al., 2017). For more information about NAP, click:
Analysis of the Selected Public Health Initiative
The rise in drug-resistant TB and the outbreaks of MDR-TB pose serious underlying problems in the health care infrastructure in the U.S. For instance, there is an increasing proportion of TB in people who were born in other countries or who are homeless, who have a mental illness or substance use, or other socioeconomic or medical problems, such as HIV, that make compliance with treatment difficult (De Vries et al., 2017; Nash et al., 2021). Thus, cultural concepts about illness causation and associated behaviors should be considered priorities to facilitate improvement in the initiative performance. Also, unethical exposure of TB patients to discriminative issues due to prejudice and bias from health care workers may negatively impact the initiative (Nash et al., 2021). Socioeconomic and patient factors such as behavior, demographic characteristics, and attitudes can lead to unfavorable MDR-TB treatment outcomes. Also, cases of unfavorable treatment outcomes may give rise to further transmission of MDR-TB, risking the development of extensive drug resistance (De Vries et al., 2017).
